ZNF384-rearranged B-ALL show a characteristic immunophenotype, with low CD10 expression and expression of myeloid markers CD13 and/or CD33, while clinical features depend on the functional defect of the different fusion partner genes. This evidence concerns the gene ZNF384 and acute lymphoblastic leukemia.